The Cross Cancer Institute, the tertiary cancer centre for Northern Alberta, provides radiation oncology services to a large geographical area with a population of over 1.5 million, and sees over 4,000 patients annually.
The Division of Radiation Oncology currently has 25 radiation oncologists, 2 nurse practitioners, and 1 neuro-oncologist.
The Division is active in IMRT and molecular imaging research, and is committed to RTOG and NCIC clinical trials with a large number of in-house studies under the rubric of the Image-Guided Adaptive Radiotherapy (IGAR) working group.
Our members also collaborate in the Centre for Biological Imaging and Adaptive Radiotherapy (CBIAR) at CCI, which houses a cyclotron for research PET radiopharmaceutical production and imaging, a 6MV helical Tomotherapy unit for image-guided RT research, a 3-Tesla Philips MR unit for biological targeting in clinical treatment planning research, and a 9.4-Tesla basic science research magnet. A stereotactic body RT program for lung cancer has been developed using the Varian Trilogy platform. In addition, our Division has active interests in interstitial brachytherapy (iodine-125) for early prostate cancer and a developing interest in MR-guided brachytherapy for gynecological cancers.
Finally, several of our faculty members are involved in translational studies involving tumor and normal tissue radiosensitivity.